{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:47:08Z","timestamp":1791654428580,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07986-6","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:47:39Z","timestamp":1773240459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Butyrate-producing Eubacterium rectale inhibits gastric carcinogenesis and augments the efficacy of immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"3","key":"7986_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics, 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349","journal-title":"CA Cancer J Clin"},{"issue":"10418","key":"7986_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208","journal-title":"Lancet"},{"issue":"10294","key":"7986_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340","journal-title":"Lancet"},{"issue":"10494","key":"7986_CR4","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY, et al. Gastric cancer. Lancet. 2025;405(10494):2087\u2013102","journal-title":"Lancet"},{"issue":"10","key":"7986_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380","journal-title":"JAMA Oncol"},{"issue":"9","key":"7986_CR6","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.ccell.2025.07.002","volume":"43","author":"ZY Wu","year":"2025","unstructured":"Wu ZY, Wu QW, Han Y, Xiang SJ, Wang YN, Wu WW, et al. Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors. Cancer Cell. 2025;43(9):1714\u201330 e 1712","journal-title":"Cancer Cell"},{"issue":"2","key":"7986_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","volume":"164","author":"D Chrysostomou","year":"2023","unstructured":"Chrysostomou D, Roberts LA, Marchesi JR, Kinross JM. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology. 2023;164(2):198\u2013213","journal-title":"Gastroenterology"},{"issue":"4","key":"7986_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cmet.2024.12.013","volume":"37","author":"X Zhu","year":"2025","unstructured":"Zhu X, Hu M, Huang X, Li L, Lin X, Shao X, et al. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses. Cell Metab. 2025;37(4):806\u201323 e806","journal-title":"Cell Metab"},{"issue":"9","key":"7986_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41423-025-01326-2","volume":"22","author":"M Xie","year":"2025","unstructured":"Xie M, Li X, Lau HC, Yu J. The gut microbiota in cancer immunity and immunotherapy. Cell Mol Immunol. 2025;22(9):1012\u201331","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"7986_CR10","doi-asserted-by":"publisher","first-page":"101355","DOI":"10.1016\/j.xcrm.2023.101355","volume":"5","author":"S Cheng","year":"2024","unstructured":"Cheng S, Han Z, Dai D, Li F, Zhang X, Lu M, et al. Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy. Cell Rep. Med. 2024;5(1):101355","journal-title":"Cell Rep. Med"},{"issue":"20","key":"7986_CR11","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1016\/j.cell.2025.06.018","volume":"188","author":"CM Phelps","year":"2025","unstructured":"Phelps CM, Willis NB, Duan T, Lee AH, Zhang Y, Rodriguez JD, et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell. 2025;188(20):5680\u2013700 e 5628","journal-title":"Cell"},{"key":"7986_CR12","doi-asserted-by":"crossref","unstructured":"Liao Q, Zhou X, Wu L, Yang Y, Zhu X, Liao H, et al. Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs. J Clin Invest. 2025;135(11)","DOI":"10.1172\/JCI181243"},{"issue":"3","key":"7986_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med. 2022;28(3):545\u201356","journal-title":"Nat Med"},{"issue":"1","key":"7986_CR14","doi-asserted-by":"publisher","first-page":"2486519","DOI":"10.1080\/19490976.2025.2486519","volume":"17","author":"M Huang","year":"2025","unstructured":"Huang M, Ji Q, Huang H, Wang X, Wang L. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification. Gut Microbes. 2025;17(1):2486519","journal-title":"Gut Microbes"},{"issue":"1","key":"7986_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41392-025-02226-7","volume":"10","author":"M Cao","year":"2025","unstructured":"Cao M, Deng Y, Hao Q, Yan H, Wang QL, Dong C, et al. Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment. Signal Transduct Target Ther. 2025;10(1):140","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"7986_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28(2):315\u201324","journal-title":"Nat Med"},{"issue":"5","key":"7986_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","volume":"31","author":"J Ss","year":"2023","unstructured":"Ss J, Yl X, Xy X, Zr K, Xl L, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31(5):781\u201397 e789","journal-title":"Cell Host Microbe"},{"issue":"6","key":"7986_CR18","doi-asserted-by":"publisher","first-page":"114306","DOI":"10.1016\/j.celrep.2024.114306","volume":"43","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Huang J, Zhang Y, Hou W, Chen F, Mo YY, et al. Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila. Cell Rep. 2024;43(6):114306","journal-title":"Cell Rep"},{"issue":"10","key":"7986_CR19","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/0008-5472.CAN-24-2580","volume":"85","author":"T Zhang","year":"2025","unstructured":"Zhang T, Li Y, Zhai E, Zhao R, Qian Y, Huang Z, et al. Intratumoral Fusobacterium nucleatum recruits tumor-associated neutrophils to promote gastric cancer progression and immune evasion. Cancer Res. 2025;85(10):1819\u201341","journal-title":"Cancer Res"},{"issue":"8","key":"7986_CR20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.chom.2022.07.003","volume":"30","author":"H Lu","year":"2022","unstructured":"Lu H, Xu X, Fu D, Gu Y, Fan R, Yi H, et al. Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4\/MyD88\/NF-kappaB axis. Cell Host Microbe. 2022;30(8):1139\u201350 e 1137","journal-title":"Cell Host Microbe"},{"issue":"4","key":"7986_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/gutjnl-2024-333530","volume":"74","author":"Z Shi","year":"2025","unstructured":"Shi Z, Li M, Zhang C, Li H, Zhang Y, Zhang L, et al. Butyrate-producing Faecalibacterium prausnitzii suppresses natural killer\/T-cell lymphoma by dampening the JAK-STAT pathway. Gut. 2025;74(4):557\u201370","journal-title":"Gut"},{"issue":"1","key":"7986_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/HEP.0000000000000047","volume":"78","author":"Y Che","year":"2023","unstructured":"Che Y, Chen G, Guo Q, Duan Y, Feng H, Xia Q. Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis. Hepatology. 2023;78(1):88\u2013102","journal-title":"Hepatology"},{"issue":"2","key":"7986_CR23","doi-asserted-by":"publisher","first-page":"2249143","DOI":"10.1080\/19490976.2023.2249143","volume":"15","author":"X Zhu","year":"2023","unstructured":"Zhu X, Li K, Liu G, Wu R, Zhang Y, Wang S, et al. Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes. 2023;15(2):2249143","journal-title":"Gut Microbes"},{"issue":"7480","key":"7986_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature12726","volume":"504","author":"N Arpaia","year":"2013","unstructured":"Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, DeRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451\u201355","journal-title":"Nature"},{"key":"7986_CR25","doi-asserted-by":"crossref","unstructured":"Shi J, Mao W, Song Y, Wang Y, Zhang L, Xu Y, et al. Butyrate alleviates food allergy by improving intestinal barrier integrity through suppressing oxidative stress-mediated notch signaling. Imeta. 2025;4(3):e70024","DOI":"10.1002\/imt2.70024"},{"issue":"10","key":"7986_CR26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1136\/gutjnl-2025-335306","volume":"74","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Song W, Zhou L, Wei S, Xu L, Li X, et al. Bacteria-metabolite butyrate boosts anti-PD1 efficacy in colorectal cancer patient-derived organoids through activating autologous tumour-infiltrating GNLY (+)CD8(+) T cells. Gut. 2025;74(10):1755\u201358","journal-title":"Gut"},{"issue":"1","key":"7986_CR27","doi-asserted-by":"publisher","first-page":"2300846","DOI":"10.1080\/19490976.2023.2300846","volume":"16","author":"SY Lee","year":"2024","unstructured":"Lee SY, Jhun J, Woo JS, Lee KH, Hwang SH, Moon J, et al. Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer. Gut Microbes. 2024;16(1):2300846","journal-title":"Gut Microbes"},{"issue":"4","key":"7986_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.gastro.2024.05.014","volume":"167","author":"R Wang","year":"2024","unstructured":"Wang R, Li B, Huang B, Li Y, Liu Q, Lyu Z, et al. Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis. Gastroenterology. 2024;167(4):733\u201349 e733","journal-title":"Gastroenterology"},{"key":"7986_CR29","first-page":"0127","volume":"6","author":"N Liu","year":"2023","unstructured":"Liu N, Chen L, Yan M, Tao Q, Wu J, Chen J, et al. Eubacterium rectale improves the efficacy of anti-PD1 immunotherapy in melanoma via l-serine-mediated NK cell activation. Res (Wash D C). 2023;6:0127","journal-title":"Res (Wash D C)"},{"issue":"9","key":"7986_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nmeth.1650","volume":"8","author":"D Knights","year":"2011","unstructured":"Knights D, Kuczynski J, Charlson ES, Zaneveld J, Mozer MC, Collman RG, et al. Bayesian community-wide culture-independent microbial source tracking. Nat Methods. 2011;8(9):761\u201363","journal-title":"Nat Methods"},{"issue":"4","key":"7986_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune Checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355","journal-title":"Cancer Cell"},{"key":"7986_CR32","doi-asserted-by":"crossref","unstructured":"Zeng D, Yu Y, Qiu W, Ou Q, Mao Q, Jiang L, et al. Immunotyping the tumor microenvironment reveals molecular heterogeneity for personalized immunotherapy in cancer. Adv Sci (Weinh). 2025;12(25):e2417593","DOI":"10.1002\/advs.202417593"},{"key":"7986_CR33","doi-asserted-by":"crossref","unstructured":"Zhao CN, Li SS, Yau T, Chen WQ, Ji R, Guan XY, et al. Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. Cell Rep. Med. 2025;102370","DOI":"10.1016\/j.xcrm.2025.102370"},{"key":"7986_CR34","doi-asserted-by":"crossref","unstructured":"Xie M, Yuan K, Zhang Y, Zhang Y, Zhang R, Gao J, et al. Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. Cancer Cell. 2025","DOI":"10.1016\/j.ccell.2025.07.012"},{"issue":"22","key":"7986_CR35","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1158\/0008-5472.CAN-23-0605","volume":"83","author":"Y Gao","year":"2023","unstructured":"Gao Y, Xu P, Sun D, Jiang Y, Lin XL, Han T, et al. Faecalibacterium prausnitzii abrogates intestinal toxicity and promotes tumor immunity to increase the efficacy of dual CTLA4 and PD-1 Checkpoint blockade. Cancer Res. 2023;83(22):3710\u201325","journal-title":"Cancer Res"},{"issue":"10","key":"7986_CR36","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","volume":"42","author":"X Wang","year":"2024","unstructured":"Wang X, Fang Y, Liang W, Wong CC, Qin H, Gao Y, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024;42(10):1729\u201346 e 1728","journal-title":"Cancer Cell"},{"issue":"5","key":"7986_CR37","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","volume":"33","author":"Y He","year":"2021","unstructured":"He Y, Fu L, Li Y, Wang W, Gong M, Zhang J, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 2021;33(5):988\u20131000 e 1007","journal-title":"Cell Metab"},{"issue":"1","key":"7986_CR38","doi-asserted-by":"publisher","first-page":"2519706","DOI":"10.1080\/19490976.2025.2519706","volume":"17","author":"M Zhang","year":"2025","unstructured":"Zhang M, Huang X, Zhang Y, Yu M, Yuan X, Xu Y, et al. Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration. Gut Microbes. 2025;17(1):2519706","journal-title":"Gut Microbes"},{"issue":"11","key":"7986_CR39","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1136\/gutjnl-2023-330291","volume":"72","author":"X Kang","year":"2023","unstructured":"Kang X, Liu C, Ding Y, Ni Y, Ji F, Lau HCH, et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. Gut. 2023;72(11):2112\u201322","journal-title":"Gut"},{"key":"7986_CR40","doi-asserted-by":"crossref","unstructured":"Chen H, Peng S, Dai L, Zou Q, Yi B, Yang X, et al. Oral microbial community assembly under the influence of periodontitis. PLoS One. 2017;12(8):e0182259","DOI":"10.1371\/journal.pone.0182259"},{"key":"7986_CR41","doi-asserted-by":"crossref","unstructured":"Zhou J, Ning D. Stochastic community assembly: does it matter in microbial ecology? Microbiol Mol Biol Rev. 2017;81(4)","DOI":"10.1128\/MMBR.00002-17"},{"issue":"1","key":"7986_CR42","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1038\/s41467-025-58513-y","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Wu Y, Le QV, Kim JS, Xu E, Lee J, et al. Self-disassembling nanoparticles as oral nanotherapeutics targeting intestinal microenvironment. Nat Commun. 2025;16(1):3365","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07986-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07986-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07986-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:20:29Z","timestamp":1773393629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07986-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7986"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07986-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments involving human participants were conducted in accordance with the ethical principles of the Declaration of Helsinki. The study involving patients was approved by the Ethics Committee of Fujian Provincial Cancer Hospital (approval number: SQ2019-072\u201301). All patients provided written informed consent. All animal experiments were performed in accordance with the ethical guidelines approved by the Institutional Animal Care and Use Committee of Fuzhou Cold-Spring Biology Co., LTD (approval number: IACUCBWS-PZ202507).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}